Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study
Table 4
Cox proportional hazard regression analysis for the risk of CKD for HBV and HCV medication.
Variable
Number
CKD event
Person years
IR
Crude HR (95% CI)
Adjusted HR (95% CI)
HBV patients
CHM
HBV drug
No
No
1169
107
4054
2.64
Ref.
Ref.
No
Yes
1080
134
5431
2.47
0.91 (0.71–1.18)
0.84 (0.65–1.10)
Yes
No
36
4
163
2.45
0.92 (0.34–2.50)
0.98 (0.36–2.67)
Yes
Yes
23
0
132
0.00
—
—
HCV patients
CHM
HCV drug
No
No
966
148
3100
4.77
Ref.
Ref.
No
Yes
1172
271
8060
3.36
0.70 (0.57–0.86)
0.66 (0.53–0.81)
Yes
No
58
5
284
1.76
0.37 (0.15–0.89)
0.52 (0.21–1.28)
Yes
Yes
78
10
577
1.73
0.36 (0.19–0.68)
0.40 (0.21–0.76)
HCV and HBV patients
CHM
Both
No
No
420
48
1258
3.82
Ref.
Ref.
No
Yes
325
35
1204
2.91
0.76 (0.49–1.18)
0.69 (0.44–1.09)
Yes
No
48
4
154
2.59
0.68 (0.25–1.89)
0.69 (0.24–1.97)
Yes
Yes
20
2
82
2.43
0.63 (0.15–2.57)
0.81 (0.19–3.39)
IR, incidence rates, HR, hazard ratio; CI, confidence interval. Adjusted HR: adjusted for sex, age, and all comorbidites in Cox proportional hazards regression. value <0.05; value <0.01; value <0.001.
